PACE GARY W 4

What Happened
Gary W. Pace, a director of Cardiff Oncology, received a grant of 40,565 derivative shares on June 11, 2026. The Form 4 reports acquisition of 40,565 shares at $0.00 (transaction code A — award/grant), so no cash was paid in connection with this award. This is a compensation/award transaction rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed after the transaction date).
• Transaction type/code: A (Grant, award or other acquisition — derivative).
• Shares acquired: 40,565 derivative shares at $0.00 (total cash paid reported as $0).
• Shares owned after transaction: Not specified in the filing.
• Footnotes/plan details: The Form 4 does not describe vesting, conversion, or tax‑withholding details; award type (e.g., RSUs vs. restricted stock) is not specified.
• Timeliness: Filing date (6/15) is later than the common 2‑business‑day Form 4 reporting window (transaction on 6/11), so the report appears delayed.

Context
This was an equity award to a director (a common form of compensation) and does not represent an open‑market buy or sell that would directly signal personal investment conviction. For derivative awards, key investor considerations are vesting schedules and whether shares become freely tradable later; those details were not provided in this filing.